evipedia.ai
← Back

Trekrezan for Health & Longevity

Evidence Review created on 10/02/2026 using AI4L / Opus 5.5

Also known as: Trecrezan, Trecresan, Trekresan, Crezacin, Cresacin, Krezatsin, Oxyethylammonium Methylphenoxyacetate, tris(2-hydroxyethyl)ammonium 2-methylphenoxyacetate, Triethanolammonium o-Cresoxyacetate, Trekvert, Trekvion, Trekresil, Trekrezolid, Immunotrezan, Trivisan-SZ

Motivation

Trekrezan (also spelled trecrezan) is a synthetic compound developed in Siberia and sold in Russian pharmacies as an over-the-counter oral tablet. Chemically, it is a salt that pairs an ingredient widely used in medicines and cosmetics with an acid that resembles a plant growth hormone. It is marketed as a way to raise the body’s general resistance to stress and to support immune function.

The compound began as a growth stimulant for crops and livestock before researchers turned to its effects on immune function and on tolerance of cold and thin air. Nearly all of that work took place in Russian laboratories and appeared in Russian-language journals, which has kept it largely unknown to health-minded people elsewhere. Interest has grown as people look for ways to strengthen resilience against infections and physical strain with age.

This review examines what is known about trekrezan’s proposed benefits, its risks, how it is taken, and how much of the evidence comes from sources independent of its developers, in order to judge its relevance as a health and longevity intervention.

Benefits - Risks - Protocol - Conclusion

This section lists in-depth articles that discuss trekrezan by name and give an overview of its chemistry, pharmacology, or human use.

Only two items are listed: no blog posts, podcasts, videos, or expert commentary on trekrezan exist in English, the two 2007 developer-group reviews are paywalled, and the remaining literature consists of narrow Russian-language laboratory papers rather than overviews.

No trekrezan content was found from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine, or Lifespan.io; the compound is a Russian pharmaceutical with almost no presence in English-language longevity media.

Grokipedia

No Grokipedia article on trekrezan exists as of October 1, 2026.

Examine

No Examine article on trekrezan exists. Examine.com does not typically cover prescription or region-specific pharmaceutical drugs, and trekrezan is a Russian pharmacy drug rather than a dietary supplement.

ConsumerLab

No ConsumerLab article on trekrezan exists. ConsumerLab does not typically cover prescription or foreign pharmaceutical drugs, and trekrezan is sold as a registered drug in Russia rather than as a dietary supplement.

Systematic Reviews

No systematic reviews or meta-analyses for Trekrezan were found on PubMed as of October 1, 2026.

Mechanism of Action

Trekrezan is a protatrane: a salt pairing triethanolamine (an amino-alcohol used in drugs and cosmetics), whose proton sits in a cage of internal hydrogen bonds, with 2-methylphenoxyacetic acid, a relative of plant growth hormones. No molecular target has been identified; the developer’s group describes several actions:

  • Immune signaling: Labeling states that it raises interferons (antiviral signaling proteins) and macrophage (debris-clearing white cell) activity; mouse and cell studies report more antibody production and B-lymphocyte (antibody-producing white cell) proliferation (Shirinskii et al., 1993).
  • Protein-building enzymes: In rats it increased mRNA (the gene message used to build a protein) for tryptophanyl-tRNA synthetase (an enzyme that loads tryptophan for protein building), whose fragments restrain blood-vessel growth (Nurbekov et al., 2011).
  • Energy and antioxidant effects: It raised ATP (the cell’s energy currency) in stressed rat tissue (Zarubina et al., 2006) and reduced lipid peroxidation (oxidative damage to fats) in rat liver (Korda, 1998).

A competing reading holds that these are nonspecific stress responses, reported mostly by one research network.

Pharmacology: Labeling reports high oral bioavailability (share absorbed into the blood), rapid liver metabolism, and kidney excretion mainly as glucuronides (conjugates made by UGT enzymes, which attach sugar groups for excretion), without accumulation. Half-life, selectivity, tissue distribution, and the specific UGT or CYP (cytochrome P450, the main drug-metabolizing liver enzymes) enzymes involved are unpublished; triethanolamine itself leaves the body largely unchanged in urine (review by Knaak et al., 1997).

Historical Context & Evolution

Trekrezan grew out of work by chemist Mikhail Voronkov at the Irkutsk Institute of Organic Chemistry in Siberia. In the early 1970s his group found that converting biologically active acids into triethanolamine salts increased their water solubility and broadened their effects. The first such salt, trekrezan, had its crystal structure solved in 1981 and was originally used in agriculture as “crezacin,” a stimulant of seed germination, crop yield, livestock reproduction, and microbial fermentation.

Animal studies in the 1980s and 1990s reported immune, blood-forming, liver-regenerating, and stress-protective effects, and the Russian Ministry of Health approved it as an adaptogen and immunomodulator (immune-regulating agent). Its current over-the-counter registration dates from 2009 and was renewed in 2025. Military physiologists later tested it as a “meteoadaptogen” (an aid to weather and climate adaptation) for cold and altitude stress.

Interest for health optimization stems from the Soviet adaptogen tradition, which placed it alongside ginseng and eleuthero, and from claims of broad protection against oxidative stress, infection, and toxins (Kondratenko & Kochina, 2021). The reported findings, such as stronger antibody responses in mice (Voronkov et al., 2004), faster liver regrowth in rats (Rasulov et al., 1992), and preserved performance in young men exposed to cold (Zarubina et al., 2008), have been neither replicated nor contradicted outside Russia. The standard of proof has since changed: randomized, independent trials are now expected, and trekrezan has had none. No lifespan study exists in any species, so its longevity standing rests on extrapolation from stress and immune findings.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no outcome has been measured in more than one controlled human trial, and the human data consist of one small cold-exposure study and one heart-failure biomarker study.

Medium 🟩 🟩

No benefit reaches Medium: the single human performance study does not report a control design in its indexed abstract, and no consistent observational data exist.

Low 🟩

Physical Performance Under Stress

Russian labeling claims better physical and mental work capacity under stress, backed by animal immobilization-stress data. The sole indexed human test gave 75 young men 0.2 g before 40 minutes at −10 °C, reportedly preventing cold-induced performance and metabolic declines. No control design, effect sizes, or cognitive benefit is reported.

Magnitude: Direction only: physical-activity and metabolic measures, including antioxidant enzymes, stayed near pre-exposure values after one 0.2 g dose before a single cold exposure; the literature reports no outcome figure (Zarubina et al., 2008).

Resistance to Acute Respiratory Viral Infections

Russian labeling lists prevention and add-on treatment of acute respiratory viral infections, attributed to interferon stimulation; a developer-affiliated review repeats this use (review by Kondratenko & Kochina, 2021). The registration studies behind this indication are unpublished in indexed journals, so their design cannot be assessed.

Magnitude: A Russian study cited in 2014 manufacturer labeling commentary reported 55% lower incidence of acute respiratory illness, but its design and size are unpublished in indexed literature (RLS drug encyclopedia entry).

Speculative 🟨

Add-On Support in Chronic Illness

A developer-affiliated review reports add-on use in tuberculosis, chronic illness, and coronavirus recovery (Kondratenko & Kochina, 2021). The only patient study measured oxidation markers (Sabadyshin et al., 1998). The basis is anecdotal and biomarker-level only.

Immune Stimulation

In mice, trekrezan increased antibody production after vaccination (Voronkov et al., 2004), and it stimulated human B-lymphocyte growth in cultures (Shirinskii et al., 1993). The basis is animal and cell work only.

Anti-Inflammatory Effects

In animal studies, trekrezan showed steady anti-inflammatory activity (Shirinskii et al., 1993) and normalized immune measures in rats with experimental bronchopneumonia (lung inflammation) (Zarubina et al., 2006). The basis is animal data only.

Correction of Anemia

In mice with graft-versus-host reaction (immune attack by transplanted cells, causing immune deficiency and anemia), trekrezan corrected anemia and restored antibody responses. The basis is animal data only (Sukhenko et al., 2001).

Antioxidant Protection

Trekrezan inhibited oxidation of human LDL (low-density lipoprotein, the main cholesterol carrier) in laboratory tests (Korda, 1997). The basis is laboratory work plus unvalidated oxidation markers in a heart-failure study (Sabadyshin et al., 1998).

Cardiovascular Protection

In cholesterol-fed rabbits, trekrezan limited aortic plaque changes (Voronkov et al., 2010). It inhibited human platelet (clotting cell) clumping in laboratory tests (Mirskova et al., 2010). Evidence is animal or cell-based.

Liver Protection and Regeneration

In rats, trekrezan (as cresacin) reduced toxin-induced liver damage and accelerated liver regrowth after partial removal. The basis is animal data only (Korda, 1998; Rasulov et al., 1992).

Tolerance of Low Oxygen

In rats trained under intermittent low-oxygen exposure, trekrezan strengthened adaptive energy-metabolism changes in brain, heart, and liver. Evidence is limited to animal data (Zarubina, 2008).

Anticancer Activity

Triethanolamine salts of this chemical family showed tumor-suppressing activity in rodents; the strongest data concern the chlorinated analog chlorocrezacin rather than trekrezan itself. No human cancer data exist (Voronkov et al., 2002).

Protection Against Toxins and Radiation

Apart from the liver, a developer-affiliated review reports animal protection against microwave irradiation; 2014 labeling added heavy-metal poisoning and alcohol withdrawal. Evidence is animal and labeling-based (review by Kondratenko & Kochina, 2021).

Fertility and Offspring Viability ⭕️ Not Central to Health & Longevity

In rats and rabbits, trekrezan was reported to improve reproductive performance and offspring survival. This bears on reproduction, not adult health or aging; the basis is animal data only (Voronkov et al., 1999).

Benefit-Modifying Factors

  • Genetic polymorphisms: No pharmacogenetic studies (of how genes shape drug response) exist. Because the acid is cleared as glucuronides, reduced-function UGT1A1 variants (as in Gilbert syndrome, a harmless inherited slowing of bilirubin processing) could alter exposure, but the responsible UGT enzyme is unknown.
  • Baseline immune and blood counts: Animal studies show normalization of depressed immune and red-cell measures rather than enhancement of normal ones, suggesting any benefit concentrates in people with low lymphocyte counts, anemia, or frequent infections.
  • Sex: The only human performance study enrolled men aged 20–24 (Zarubina et al., 2008). No data exist on women, so sex differences in benefit are unknown.
  • Pre-existing conditions: Reported add-on benefits come from people with tuberculosis, heart failure, or post-infection recovery. Healthy adults may see smaller changes, consistent with the normalizing pattern in animal work.
  • Age: No study enrolled older adults. Age-related immune decline could make immune support more relevant after 65, while labeling reports unchanged absorption and clearance in older people.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse-event rates from more than one controlled human trial have been published; safety information comes from labeling, rodent toxicology, and data on the triethanolamine component.

Medium 🟥 🟥

No risk reaches Medium: human safety data are limited to post-marketing reports summarized in labeling without frequencies, and the remaining data are rodent toxicology and patch testing of the triethanolamine component.

Low 🟥

Allergic Reactions Including Anaphylaxis

Russian labeling lists rare hypersensitivity reactions, including anaphylaxis (a severe whole-body allergic reaction) and angioedema (deep swelling of lips, tongue, or throat). These come from post-marketing experience without published frequencies. Triethanolamine, one component, is a very weak skin sensitizer in patch-test surveillance.

Magnitude: Allergic reactions are described as rare without a published frequency; for the triethanolamine component, 0.4% of 85,098 patch-tested dermatology patients reacted, many with irritant-type rather than allergic responses (Lessmann et al., 2009).

Speculative 🟨

Carcinogenicity Signal From Triethanolamine ⚠️ Conflicted

Skin-applied triethanolamine raised female-mouse liver adenomas (benign tumors) (toxicology report, 2004); long-term cresacin did not raise rodent tumors (Tsapenko et al., 1986), plausibly reflecting dose, route, or compound differences. Net reading: no human-relevant signal.

Kidney and Liver Changes at High Exposure

High triethanolamine doses caused rodent kidney and liver changes, far above the roughly 95 mg per 200 mg tablet. No human organ toxicity is reported; basis is animal data (review by Knaak et al., 1997).

Increased Bleeding Tendency

Trekrezan inhibited human platelet (clotting cell) aggregation in laboratory tests, suggesting possible additive bleeding with anticoagulants (clot-preventing drugs). No bleeding events have been reported; the basis is laboratory data only (Mirskova et al., 2010).

Immune Overstimulation in Autoimmune Disease

As an immune stimulant, trekrezan could theoretically worsen autoimmune conditions. No cases are reported; the basis is mechanistic only (Shirinskii et al., 1993).

Liver Enzyme Induction

Related phenoxyacetic acids, including derivatives of the herbicide MCPA (4-chloro-2-methylphenoxyacetic acid), induced cytochrome P450 enzymes in rats. Whether trekrezan does so in humans is untested; the basis is animal data (Inomata et al., 1991).

Blood-Glucose Effects in Diabetes

Russian labeling advises caution in diabetes without stating a mechanism or supporting data. The basis is a regulatory precaution only; no published study has measured trekrezan’s effect on blood glucose.

Risk-Modifying Factors

  • Genetic polymorphisms: No pharmacogenetic data exist. Reduced glucuronidation capacity, as with UGT1A1 variants in Gilbert syndrome, could theoretically raise exposure to the acid component.
  • Baseline biomarkers: Raised fasting glucose or HbA1c (average blood sugar over about three months) matters given the diabetes caution; reduced eGFR (estimated kidney filtration rate) could slow triethanolamine clearance; low platelet counts heighten bleeding concerns.
  • Sex: No sex-specific safety data exist. Women who are pregnant or breastfeeding fall under the labeled contraindication, based on absent safety data.
  • Pre-existing conditions: Prior anaphylaxis, autoimmune disease, bleeding disorders, diabetes, and lactose intolerance (each tablet contains about 200 mg lactose) raise the relevance of the identified risks.
  • Age: Labeling reports unchanged pharmacokinetics (absorption and clearance) in older adults, but older people more often take anticoagulants and immunosuppressants (drugs that dampen immunity), widening theoretical interaction risks.

Key Interactions & Contraindications

Russian labeling reports no known undesirable drug interactions. The interactions below are theoretical, derived from trekrezan’s reported actions.

  • Clot-reducing drugs (warfarin, apixaban, clopidogrel, aspirin): Caution. Anticoagulants and antiplatelet drugs (which block platelet clumping) both reduce clotting; laboratory platelet inhibition suggests possible additive bleeding. Warfarin users can check INR (a clotting-time ratio) within a week of starting and watch for bruising.
  • Immunosuppressants (tacrolimus, cyclosporine, prednisone, methotrexate): Relative contraindication. Immune stimulation could oppose intended suppression, risking transplant rejection or autoimmune flare. Avoidance during treatment removes the conflict.
  • Glucose-lowering drugs (metformin, insulin, glipizide): Monitor. Labeling urges caution in diabetes, so unexpected glucose shifts are possible, including with sulfonylureas (drugs that prompt insulin release) such as glipizide. Home glucose checks during a course detect changes.
  • Drugs cleared by glucuronidation (lamotrigine, valproate, mycophenolate): Monitor. Competition for UGT enzymes could theoretically alter drug levels; this has not been tested. Drug-level checks after a course address the uncertainty.
  • Over-the-counter pain relievers (ibuprofen, naproxen, acetaminophen): Monitor. Ibuprofen and naproxen add antiplatelet effects, raising theoretical bleeding risk; acetaminophen shares glucuronidation, so its levels could shift. The lowest effective dose limits overlap.
  • Antiplatelet supplements (fish oil, Ginkgo biloba, vitamin E, garlic extract): Monitor. Additive bleeding tendency in theory. Pausing high doses around surgery limits risk.
  • Immune-stimulating supplements (echinacea, Eleutherococcus senticosus, Panax ginseng, Rhodiola rosea): Monitor. Additive immune effects could theoretically trigger autoimmune flares; no harmful reports exist. Avoiding the combination in autoimmune disease removes this risk.
  • Vaccination: Monitor. Mouse data show enhanced antibody responses after vaccination (Voronkov et al., 2004); the possible consequence is a stronger antibody response or more pronounced post-vaccination reactions, untested in humans.

Populations who should avoid Trekrezan:

  • Pregnant or breastfeeding women (labeled contraindication; no safety data)
  • Children under 12 years (labeled contraindication)
  • People with prior hypersensitivity, anaphylaxis, or angioedema to trekrezan or its tablet ingredients
  • People with hereditary lactose intolerance, lactase deficiency, or glucose-galactose malabsorption (an inherited inability to absorb these sugars from the gut)
  • Organ-transplant recipients on maintenance immunosuppression (theoretical)
  • People with active autoimmune disease requiring immunosuppressive therapy (theoretical)

Risk Mitigation Strategies

  • Labeled short courses: Limiting use to 200 mg daily for 8–14 days (600 mg on day 1 where labeled) stays within tolerated exposure and limits unknown cumulative effects, including from the triethanolamine component.
  • First-dose observation: Taking the first tablet at home, with no driving or travel planned for 2 hours, allows prompt response to anaphylaxis or angioedema; any swelling or breathing difficulty calls for emergency care.
  • Glucose checks in diabetes: Home glucose readings once or twice daily during a course detect the unexpected glucose shifts flagged by the labeling caution.
  • Bleeding vigilance on anticoagulants: An INR check within 5–7 days of starting (warfarin users) and attention to bruising or gum bleeding address the theoretical additive bleeding risk.
  • Avoidance during immunosuppression: Skipping trekrezan during immunosuppressive treatment or active autoimmune flares avoids the theoretical risk of counteracting therapy or triggering flares.
  • Periodic labs for repeat users: Liver enzymes and kidney function every 6–12 months for those taking several courses a year address the rodent liver and kidney findings for triethanolamine.

Therapeutic Protocol

  • Labeled stress and performance course: Developed by the Irkutsk Institute of Chemistry program and set in Russian labeling: 600 mg (three 200 mg tablets) on day 1, then 200 mg daily for 7 days, after meals; 2,000 mg total.
  • Labeled prevention course: 200 mg once daily after a meal for 14 days (2,800 mg total), used during seasonal respiratory-infection periods.
  • Single pre-exposure dose: Zarubina and Shabanov at the Military Medical Academy in St. Petersburg gave one 0.2 g oral dose before cold exposure, framing trekrezan as an acute “meteoadaptogen” rather than a course (Zarubina et al., 2008).
  • Older labeled detoxification regimen: 2014 labeling listed 400–600 mg daily for at least 5 days as add-on care in heavy-metal poisoning and alcohol withdrawal.
  • Longevity-specific use: No practitioner or clinic has published a longevity protocol; neither continuous daily use nor repeated courses has been studied for aging outcomes.
  • Time of day: Labeling specifies dosing after meals but no time of day. Morning or midday dosing is conventional for adaptogens; no sleep effects are reported.
  • Half-life: Human half-life is unpublished. Labeling reports rapid liver metabolism, kidney excretion as glucuronides, and no accumulation with repeated use, consistent with once-daily dosing.
  • Single vs. split dosing: Maintenance days use one 200 mg dose; the 600 mg first day of the treatment regimen is labeled as one tablet three times daily.
  • Genetic polymorphisms: No pharmacogenetic dosing guidance exists; carriers of UGT1A1 variants have no established dose adjustment.
  • Sex differences: No sex-specific dosing exists; human performance data come only from young men.
  • Age: Labeling applies the same dose from age 12 and reports unchanged pharmacokinetics in older adults; no data specific to people over 65 exist.
  • Baseline biomarkers: No biomarker-guided dosing exists. Animal data suggest effects mainly where immune or blood counts are depressed, so baseline lymphocyte count and hemoglobin frame expected response.
  • Pre-existing conditions: Labeling requires no dose change in liver or kidney impairment but advises caution in diabetes; immunosuppressed and autoimmune patients fall outside studied use.

Discontinuation & Cycling

  • Short-term by design: Trekrezan is labeled for 8–14-day courses, not lifelong use; no data support continuous long-term intake.
  • Withdrawal effects: None reported. The compound does not accumulate, and no rebound in immune or stress measures has been described.
  • Tapering: Not needed; labeled courses end abruptly without a taper.
  • Cycling: 2014 Russian labeling allowed repeat courses after 1–2-month intervals (RLS drug encyclopedia entry). Whether cycling preserves efficacy has not been studied, and no tolerance has been documented.
  • Stopping for adverse events: Any allergic sign ends a course immediately; re-exposure after anaphylaxis is contraindicated.

Sourcing and Quality

  • Registered Russian products: Trekrezan 200 mg tablets (Grotex or Farmproekt; earlier Usolye-Sibirsky Chemical-Pharmaceutical Plant) and same-substance generics such as Trekvert, Trekvion, Trekresil, Trekrezolid, and Immunotrezan.
  • Formulation: Each tablet contains 200 mg active substance plus about 200 mg lactose monohydrate, potato starch, and a lubricant; no extended-release or injectable human forms are marketed.
  • Purity: Developer-affiliated chemists reported that direct synthesis gives 75–90% yields but insufficient purity for medicine, so pharmaceutical-grade product differs from agricultural crezacin (review by Kondratenko & Kochina, 2021).
  • What to look for: A Russian registration number on the pack (LP-No(010553)-(RG-RU) or earlier LSR-008909/09), intact blister packaging, and expiry date. No USP (United States Pharmacopeia) or NSF International third-party certification exists for this drug.
  • Buying outside Russia: International online resellers carry higher counterfeit and storage risks, and batch documentation is rarely available.

Practical Considerations

  • Time to effect: The cold-exposure study (Zarubina et al., 2008) gave one dose before exposure. Labeled courses assume effects within days, and labeling calls for medical review if respiratory symptoms have not improved after 3 days.
  • Common pitfalls: Treating it as a daily longevity supplement beyond labeled courses; buying agricultural crezacin; assuming evidence comparable to Western-approved drugs; overlooking lactose content.
  • Regulatory status: A Russian over-the-counter drug classed under ATC (Anatomical Therapeutic Chemical classification) code A13A, general tonics. It is not approved by the FDA (U.S. Food and Drug Administration) or EMA (European Medicines Agency); personal-import rules vary by country.
  • Cost and accessibility: Inexpensive in Russia, roughly 550–1,200 rubles per 10–20-tablet pack in pharmacy listings, but difficult to obtain elsewhere.
  • Language barrier: Most primary literature is in Russian, which limits independent appraisal.

Interaction with Foundational Habits

  • Sleep: None known. Labeling reports no effect on alertness for driving, and no insomnia or sedation is described. No study measured sleep; morning or midday dosing avoids any unrecognized stimulating effect.
  • Nutrition: Indirect. Labeling specifies dosing after meals, and each tablet adds about 200 mg lactose. Triethanolamine can form nitrosamines (potential carcinogens) with nitrite in acidic test tubes, but mouse studies found no meaningful formation in the body (Saghir et al., 2005).
  • Exercise: Potentiating in theory. Labeling targets heavy physical exertion, and rats showed stronger metabolic adaptation to intermittent low-oxygen training (Zarubina, 2008). Whether antioxidant effects blunt training adaptations, as reported for high-dose vitamins C and E (Ristow et al., 2009), is untested; dosing away from hard sessions is a cautious option.
  • Stress management: Indirect, supportive. Marketed as a stress adaptogen, it showed protection in animal immobilization-stress models and the human cold study (Zarubina et al., 2008). No cortisol (the main stress hormone) data exist; it adds to, rather than replaces, sleep, breathing, and recovery practices.

Monitoring Protocol & Defining Success

Baseline testing: Before a first course, a complete blood count, liver enzymes, kidney function, fasting glucose with HbA1c, and hs-CRP (high-sensitivity C-reactive protein, a general inflammation marker) establish a personal reference point. Trekrezan’s claimed effects center on immune and blood-cell measures, and the liver and kidneys clear it, so these tests capture both the intended targets and the organs handling the compound. People with diabetes, autoimmune disease, or anticoagulant use have added reason to record a baseline.

Ongoing monitoring: The panel is typically repeated at the end of the first course (day 8–14), then every 6–12 months for anyone repeating courses several times a year. Because courses are short, the most useful comparison is each result against the individual’s own baseline rather than a population target. Any rash, swelling, or breathing difficulty ends a course immediately.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
CBC with differential WBC 4.5–7.5 ×10⁹/L; lymphocytes 1.5–3.0 ×10⁹/L Immune and blood-cell effects CBC = complete blood count; WBC = white blood cell count. Conventional WBC 4.0–11.0 ×10⁹/L, lymphocytes 1.0–4.8 ×10⁹/L. No fasting needed; avoid testing during acute infection
Hemoglobin Men 14–16 g/dL; women 13–15 g/dL Anemia-correction claim Conventional men 13.5–17.5 g/dL, women 12.0–15.5 g/dL; part of the CBC
ALT and AST ALT <25 U/L (men), <20 U/L (women); AST <25 U/L Liver processes the compound ALT = alanine aminotransferase, AST = aspartate aminotransferase (liver enzymes). Conventional upper limits about 40–55 U/L; avoid intense exercise 48 hours before
Creatinine and eGFR eGFR >90 mL/min/1.73 m² Kidneys clear both components eGFR = estimated glomerular filtration rate (kidney filtering capacity). Conventional >60; pair with cystatin C (an alternative kidney marker)
Fasting glucose and HbA1c Glucose 75–90 mg/dL; HbA1c <5.4% Labeled caution in diabetes HbA1c = average blood sugar over about 3 months. Conventional glucose <100 mg/dL, HbA1c <5.7%; 8–12-hour fast, morning draw
hs-CRP <1.0 mg/L Inflammation baseline for immune stimulation hs-CRP = high-sensitivity C-reactive protein (general inflammation marker). Conventional <3.0 mg/L; defer during infection

Qualitative markers:

  • Number and duration of colds or respiratory infections per season
  • Perceived energy and fatigue during demanding periods
  • Exercise tolerance and recovery after hard sessions
  • Comfort and performance in cold or at altitude
  • Sleep quality during courses
  • Any rash, itching, or swelling

Emerging Research

  • No registered trials: A ClinicalTrials.gov search on October 1, 2026 for trekrezan and its alternate names found no registered studies, so no NCT ID (registry number) exists and no trial of any phase is underway.
  • Post-COVID recovery: A 2021 review reports proposed use for lung-related aftereffects of coronavirus infection, without published controlled outcomes; a trial here could strengthen or weaken the infection-resilience case (Kondratenko & Kochina, 2021).
  • Protein-synthesis enzyme mechanism: Trekrezan raised mRNA for tryptophanyl-tRNA synthetase in rats; independent confirmation and human data would show whether this underlies immune or vascular effects (Nurbekov et al., 2011).
  • Analog compounds: Chlorocrezacin and the zinc complex zincatrane outperform trekrezan in animal work, zincatrane raising PGC-1α (a master regulator of mitochondria production) expression, which may redirect research toward analogs (review by Kondratenko & Kochina, 2021).
  • Triethanolamine safety: Female-mouse liver tumors in a U.S. National Toxicology Program skin study leave an open question for long-term oral exposure that could weaken the case (National Toxicology Program, 2004).
  • Lifespan testing gap: No lifespan study exists in worms, flies, or rodents; such data could strengthen or weaken the longevity case more than further mechanism work.

Conclusion

Trekrezan is a Russian over-the-counter salt made from a common pharmaceutical ingredient and a plant-hormone-like acid, sold to raise resistance to stress and support immunity. For health-focused adults seeking resilience tools, its appeal is breadth: laboratory and animal work describes immune stimulation, correction of anemia, liver protection, antioxidant activity, and better tolerance of thin air, and a single study in young men reported preserved performance during cold exposure.

The weight of this evidence is light. No benefit rises above a low grade, because the human data are small, sparsely described, and never repeated, while most findings come from rodents or cell cultures. Nearly all of the research was produced by the developer’s own scientific network or by collaborating Russian institutes, a conflict of interest that independent replication has not offset. Claims about respiratory infections and chronic illness rest on approval studies that are not available in major medical databases. No study has examined lifespan in any species.

The safety record appears benign but is thin. Labeling reports only rare allergic reactions, and animal harm appears only far above labeled amounts. Open questions about the common pharmaceutical ingredient it contains, blood clotting, and immune stimulation in autoimmune disease rest on indirect data.

Overall, trekrezan is an inexpensive, short-course compound with plausible but largely untested benefits, and its value for longevity remains unknown rather than disproven.

Top - Benefits - Risks - Protocol